Study Details

Back to Search Results

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01711814

Astellas Study ID

The unique identification code given by the study sponsor.

015K-CL-RA25

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2011-006021-23

Follow Trial

Condition

Rheumatoid Arthritis

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2012 - Mar 2016

Masking

None (Open Label)

Enrollment number

611

A Phase 2 Open-Label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site HU3448

Budapest, Hungary, 1027

Site CO3450

Bucaramanga, Colombia

Site US291

Wheaton, United States, 20902

Site US219

Palo Alto, United States, 94304

Site US3218

Birmingham, United States, 35216

Site US3300

Oklahoma City, United States, 73103

Site US3226

Vernon Hills, United States, 60061

Site MX3317

Morelia, Mexico, 58070

Site MX3238

Guadalajara, Mexico, 44650

Site HU3398

Bekescsaba, Hungary, 5600

Site CZ3449

Zlin, Czech Republic, 760 01

Site HU3462

Budapest, Hungary, 1027

Site PL3391

Bialystok, Poland, 15-879

Site US3298

Hickory, United States, 28602

Site CO3451

Cali, Colombia

Site US3319

Austin, United States, 78705

Site BG3613

Burgas, Bulgaria, 8000

Site US3232

Orlando, United States, 32804

Site HU3302

Budapest, Hungary, 1027

Site PL3600

Warszawa, Poland, 02-118

Site PL2893

Bydgoszcz, Poland, 85-168

Site US3306

Knoxville, United States, 37909

Site PL3233

Bialystok, Poland, 15-351

Site US702

Morton Grove, United States, 60053

Site CZ3388

Praha 2, Czech Republic, 128 50

Site US3227

Palm Desert, United States, 92260

Site PL3599

Warszawa, Poland, 02-653

Site US3329

Elizabethtown, United States, 42701

Site BG3303

Sofia, Bulgaria, 1612

Site CO2826

Bucamaranga, Colombia

Site US345

Duncansville, United States, 16635

Site US3304

Wyomissing, United States, 19610

Site MX3307

Guadalajara, Jalisco, Mexico, 44280

Site CZ3225

Uherske Hradiste, Czech Republic, 68601

Site PL3601

Lublin, Poland, 20-582

Site BE3314

Brussels, Belgium, 1190

Site PL3603

Krakow, Poland, 31-637

Site US3327

Chesapeake, United States, 23320

Site MX3310

Mexico, Mexico, 6700

Site CZ3376

Praha-Nusle, Czech Republic, 140 00

Site HU3447

Debrecen, Hungary, H-4043

Site BE3387

Brussels, Belgium, 1070

Site CO3297

Bogota, Colombia

Site US3331

Colorado Springs, United States, 80920

Site US3320

Clarksburg, United States, 26301

Site US3332

Santa Maria, United States, 93454

Site US828

LaJolla, United States, 92093-0943

Site US1894

Jacksonville, United States, 32216

Site BG3217

Plovdiv, Bulgaria, 4003

Site CO3326

Barranquilla, Atlantico, Colombia

Site HU3461

Balatonfüred, Hungary, 8230

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo